Polo-like kinase-1 as a novel target in neoplastic mast cells: demonstration of growth-inhibitory effects of small interfering RNA and the Polo-like kinase-1 targeting drug BI 2536 - Peter, B.; Gleixner, K. V.; Cerny-Reiterer, S.; Herrmann, H.; Winter, V.; Hadzijusufovic, E.; Ferenc, V.; Schuch, K.; Mirkina, I.; Horny, H.-P.; Pickl, W. F.; Mullauer, L.; et al. (Haematologica (Roma), 2011)
Keywords: Animals; Apoptosis - drug effects; Biological and medical sciences; Cell Cycle - drug effects; Cell Cycle Proteins - antagonists & inhibitors; Cell Cycle Proteins - genetics; Cell Cycle Proteins - metabolism; Cell Line, Tumor; Cell Proliferation - drug effects; Dose-Response Relationship, Drug; Flow Cytometry; Hematologic and hematopoietic diseases; HL-60 Cells; Humans; Immunohistochemistry; K562 Cells; Mast Cells - drug effects; Mast Cells - metabolism; Mast Cells - pathology; Mastocytosis, Systemic - genetics; Mastocytosis, Systemic - metabolism; Mastocytosis, Systemic - pathology; Medical sciences; Original; Phosphorylation; Polo-Like Kinase 1; Protein Serine-Threonine Kinases - antagonists & inhibitors; Protein Serine-Threonine Kinases - genetics; Protein Serine-Threonine Kinases - metabolism; Proto-Oncogene Proteins - antagonists & inhibitors; Proto-Oncogene Proteins - genetics; Proto-Oncogene Proteins - metabolism; Pteridines - pharmacology; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Thymidine - metabolism; Thymidine - pharmacokinetics; Tumor Cells, Cultured; U937 Cells; Cell proliferation; Mastocytosis; RNA interference; Targeting; Hematology; Plk-1; siRNA; Malignant tumor; Gene silencing; Cell death; C-Onc gene; Targeted drug; KIT; Mast cell; Target cell; targeted drugs; Protooncogene; Cancer; Apoptosis